<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380834</url>
  </required_header>
  <id_info>
    <org_study_id>PRO10060554</org_study_id>
    <nct_id>NCT01380834</nct_id>
    <nct_alias>NCT01231048</nct_alias>
  </id_info>
  <brief_title>Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Pediatric Patients</brief_title>
  <official_title>Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Laparoscopic Cholecystectomy: a Prospective, Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mihaela Visoiu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy of paravertebral nerve blocks, single&#xD;
      shot, with ropivacaine 0.5% for postoperative pain control after elective laparoscopic&#xD;
      cholecystectomy as compared with incisional administration of same local anesthetic at&#xD;
      laparoscopic insufflation ports by the surgeon.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain after laparoscopic cholecystectomy is a result of many mechanisms such as tissue injury,&#xD;
      local trauma to gallbladder removal, chemical irritation of the peritoneum, pneumoperitoneum.&#xD;
      Effective analgesia in the immediate post-operative period following laparoscopic&#xD;
      cholecystectomy is necessary for optimal recovery. Many methods for pain control after&#xD;
      laparoscopic cholecystectomy have been evaluated, but none of them provided optimal&#xD;
      postoperative analgesia. When used as a complement to general anesthesia, bilateral&#xD;
      paravertebral blockade T5-T6 for adult laparoscopic cholecystectomy has been found to improve&#xD;
      postoperative pain control. Whether this is also the case with pediatric patients is not&#xD;
      certain. Analgesia from administration of local anesthetic by surgeon at insufflations ports&#xD;
      is of short duration and may not provide sufficient pain relief. cholecystectomy.&#xD;
&#xD;
      84 pediatric patients (8-17 yrs old) will be randomly assigned to two groups: Group 1&#xD;
      (treatment group): 42 patients will have six paravertebral nerve blocks with ropivacaine&#xD;
      0.5%, and incisional administration of placebo / normal saline at all four laparoscopic&#xD;
      ports.&#xD;
&#xD;
      Group 2 (control group): 42 patients will have placebo/normal saline in paravertebral space,&#xD;
      same amount, and injection at incision sites for all for insufflation ports with ropivacaine&#xD;
      0.5%.&#xD;
&#xD;
      Both the anesthesiologist and the surgeon will be blinded to patient randomization.&#xD;
&#xD;
      Additional postoperative pain control will be provided via patient administered dilaudid PCA,&#xD;
      for 12 hours after paravertebral block. After PCA is discontinued, the patient will receive&#xD;
      oxycodone po and dilaudid iv for breakthrough pain.&#xD;
&#xD;
      Pain assessment will continue until 24 hours after paravertebral block or patient discharge&#xD;
      if earlier than 24 hours.&#xD;
&#xD;
      The primary end-point of this research is the amount of dilaudid (ng/kg/min) administered via&#xD;
      Patient Controlled Analgesia (PCA), 12 hours after administration of ropivacaine 0.5% /normal&#xD;
      saline in paravertebral space and administration of normal saline/ropivacaine 0.5% at all&#xD;
      four laparoscopic ports.&#xD;
&#xD;
      The secondary end points will be also for total amount of fentanyl (mcg/kg), dilaudid&#xD;
      (mcg/kg), oxycodone (mg/kg) and morphine (mg/kg) (after conversion of above opioids to&#xD;
      morphine based on opioids potency) used intraoperatively and 24 hours postoperatively (or&#xD;
      until the patient is discharged, if sooner).&#xD;
&#xD;
      Postoperative pain scores will be assessed and compared at 4, 8, 12, 18 and 24 hr after&#xD;
      paravertebral block using Visual Analog Scale (VAS).&#xD;
&#xD;
      Other secondary end-points will be possible side effects from opioids administration (nausea,&#xD;
      emesis, itching, and episodes of respiratory depression) and possible complications&#xD;
      associated with nerve blocks: pleural and vascular punctures, pneumothorax, back pain,&#xD;
      bruises, and intravascular administration of local anesthetic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioids Consumption Via PCA</measure>
    <time_frame>12 hrs after the blocks were done</time_frame>
    <description>The primary end-point of this research is the amount of dilaudid (ng/kg/min) administered via Patient Controlled Analgesia (PCA), 12 hours after administration of ropivacaine 0.5% /normal saline in paravertebral space and administration of normal saline/ropivacaine 0.5% at all four laparoscopic ports.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Scores Assessed Using Visual Analog Scale (VAS).</measure>
    <time_frame>24 hrs after blocks were done or until the patient is discharged</time_frame>
    <description>The VAS (Visual Analog Scale, 0 mm &quot;no pain&quot;, to 100 mm,&quot; the worst pain possible &quot;) is used to assess postoperative pain for patients. Postoperative pain scores will be assessed and compared at 4, 8, 12, 18 and 24 hr after paravertebral block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hrs after blocks were done or until the patient is discharged</time_frame>
    <description>Other secondary end points will total amount of fentanyl (mcg/kg), dilaudid (mcg/kg), oxycodone (mg/kg) and morphine (mg/kg) (after conversion of above opioids to morphine based on opioids potency) used at 24 hours postoperatively (or until the patient is discharged, if sooner).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>= Group 2(control group)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment group</intervention_name>
    <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Group 1 ( treatment group)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pediatric patients scheduled for elective laparoscopic cholecystectomy under general&#xD;
             anesthesia&#xD;
&#xD;
          -  8-17 yrs, female and male&#xD;
&#xD;
          -  ASA 1, 2, 3&#xD;
&#xD;
          -  more than 30 Kg&#xD;
&#xD;
          -  BMI less than 36 (to calculate will use http://www.globalrph.com/bmi.htm )&#xD;
&#xD;
          -  the patient must be able to self administer opioids via patient control analgesia&#xD;
             (PCA)&#xD;
&#xD;
          -  the patient must be able to complete postoperative questionnaires for pain score, pain&#xD;
             type, location, patient satisfaction&#xD;
&#xD;
          -  the patient will to be admitted for 24 hrs after surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  parental/guardian refusal&#xD;
&#xD;
          -  history of coagulopathy, INR more than 1.5, platelets less than 100 000, PT , PTT more&#xD;
             than normal value, patient on Coumadin, heparin or low molecular weight heparin (&#xD;
             LMWH)&#xD;
&#xD;
          -  local infection at the planned block site&#xD;
&#xD;
          -  vertebral anomalies, (e.g. scoliosis)&#xD;
&#xD;
          -  BMI more or equal 36&#xD;
&#xD;
          -  patient unable to self administer medications via PCA&#xD;
&#xD;
          -  allergy to dilaudid, oxycodone, acetaminophen, ropivacaine&#xD;
&#xD;
          -  chronic opioid use&#xD;
&#xD;
          -  current weight less than 30 kg&#xD;
&#xD;
          -  acute pain (pain on day of surgery that requires pain medication)&#xD;
&#xD;
          -  pregnancy test positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihaela Visoiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHP of UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh, UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2015</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Mihaela Visoiu</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>paravertebral nerve blocks</keyword>
  <keyword>laparoscopic cholecystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="B2" value="14" lower_limit="12" upper_limit="15"/>
                    <measurement group_id="B3" value="14" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opioids Consumption Via PCA</title>
        <description>The primary end-point of this research is the amount of dilaudid (ng/kg/min) administered via Patient Controlled Analgesia (PCA), 12 hours after administration of ropivacaine 0.5% /normal saline in paravertebral space and administration of normal saline/ropivacaine 0.5% at all four laparoscopic ports.</description>
        <time_frame>12 hrs after the blocks were done</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioids Consumption Via PCA</title>
          <description>The primary end-point of this research is the amount of dilaudid (ng/kg/min) administered via Patient Controlled Analgesia (PCA), 12 hours after administration of ropivacaine 0.5% /normal saline in paravertebral space and administration of normal saline/ropivacaine 0.5% at all four laparoscopic ports.</description>
          <units>ng/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.29" spread="20.23"/>
                    <measurement group_id="O2" value="100.17" spread="46.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain Scores Assessed Using Visual Analog Scale (VAS).</title>
        <description>The VAS (Visual Analog Scale, 0 mm &quot;no pain&quot;, to 100 mm,&quot; the worst pain possible &quot;) is used to assess postoperative pain for patients. Postoperative pain scores will be assessed and compared at 4, 8, 12, 18 and 24 hr after paravertebral block.</description>
        <time_frame>24 hrs after blocks were done or until the patient is discharged</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Scores Assessed Using Visual Analog Scale (VAS).</title>
          <description>The VAS (Visual Analog Scale, 0 mm &quot;no pain&quot;, to 100 mm,&quot; the worst pain possible &quot;) is used to assess postoperative pain for patients. Postoperative pain scores will be assessed and compared at 4, 8, 12, 18 and 24 hr after paravertebral block.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4h VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.68" spread="27.48"/>
                    <measurement group_id="O2" value="38.95" spread="26.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8h VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.69" spread="30.15"/>
                    <measurement group_id="O2" value="37.67" spread="27.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.88" spread="29.16"/>
                    <measurement group_id="O2" value="36.07" spread="27.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18h VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.62" spread="31.22"/>
                    <measurement group_id="O2" value="35.73" spread="27.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24h VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.17" spread="28.73"/>
                    <measurement group_id="O2" value="29.98" spread="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>Other secondary end points will total amount of fentanyl (mcg/kg), dilaudid (mcg/kg), oxycodone (mg/kg) and morphine (mg/kg) (after conversion of above opioids to morphine based on opioids potency) used at 24 hours postoperatively (or until the patient is discharged, if sooner).</description>
        <time_frame>24 hrs after blocks were done or until the patient is discharged</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Other secondary end points will total amount of fentanyl (mcg/kg), dilaudid (mcg/kg), oxycodone (mg/kg) and morphine (mg/kg) (after conversion of above opioids to morphine based on opioids potency) used at 24 hours postoperatively (or until the patient is discharged, if sooner).</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.32"/>
                    <measurement group_id="O2" value="0.71" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.&#xD;
treatment group: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.&#xD;
control group: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vascular Puncture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mihaela Visoiu</name_or_title>
      <organization>Children's Hospital of UPMC</organization>
      <phone>412-692-5260</phone>
      <email>visoium@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

